Journal of International Psychiatry

[Abstract] Objective: To explore the value of combined therapy of agomelatine and cognitive behavioral intervention in the treatment of patients with depression after stroke. Methods: 70 patients with post-stroke depression confirmed by relevant examinations in our hospital from June 2020 to December 22 were randomly selected, and 35 patients in each group were divided into single and double groups according to the hospitalization number. The control group was treated with argomepratine, and the observation group was treated with cognitive-behavioral intervention on the basis of the control group. The recurrence rate of stroke after treatment was recorded, and the psychological status, sleep quality and cognitive level were evaluated. Results: The recurrence rate of stroke recorded in 35 patients in the observation group at 3 months (0.00%) and 6 months (5.71%) after the combined treatment of drugs and cognitive behavioral intervention was lower than that in the control group (P<0.05); The scores of anxiety, depression and sleep quality recorded in the observation group were lower than those in the control group (P<0.05); The cognitive function score recorded in the observation group was higher than that in the control group (P<0.05). Conclusion: In the treatment of post-stroke depression, the combination of agomelatine and cognitive behavioral intervention can significantly improve their anxiety and depression, sleep quality, and reduce the impact of disease on their cognitive function.

Keywords: Agomepratine; Cognitive behavior intervention; Stroke; Depression; mentality